Bodem Barbara W. 4
4 · Turning Point Therapeutics, Inc. · Filed Aug 17, 2022
Insider Transaction Report
Form 4
Bodem Barbara W.
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2022-08-17−14,995→ 0 totalExercise: $94.59Exp: 2031-03-30→ Common Stock (14,995 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").
- [F2]At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option.